Study of HTX-019 in healthy volunteers

Trial Profile

Study of HTX-019 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Aprepitant (Primary) ; Fosaprepitant
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Adverse reactions
  • Sponsors Heron Therapeutics
  • Most Recent Events

    • 09 Nov 2017 According to a Heron Therapeutics media release, the US FDA has approved CINVANTI (aprepitant) injectable emulsion, for intravenous infusion for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
    • 12 Jan 2017 According to a Heron Therapeutics media release, the company has submitted a New Drug Application (NDA) for HTX-019 (CINVANTI) for the prevention of chemotherapy induced nausea and vomiting. The filing includes data from this trial.
    • 23 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top